Rimonabant@- Anti-obesity drug- (Feb 2006)
Drug Name:
Rimonabant@- Anti-obesity drug- (Feb 2006)
List Of Brands:
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Reports not available
Indication:
Approved by US FDA in February 2006
LIST OF DRUGS DURING 2007
Sr.No- 65
Name of the Drug- Rimonabant tabet 20mg
Pharmacological classification- For Obese Patients BMI >/= 30kg/m2 or
overweight patients BMI >/= 27kg/m2 with
Associated risk factors such as Type-1 diabetes or
dyslipidemia
,
Date of Approval- 11-05-07
Approved by US FDA on 30-12-2007 (Ref- FDA approved List- 2007)
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Rimonabant Tablet 20mg 11-05-2007
For obese patients BMI 30kg/M2 or overweight patients BMI 27kg/M2
with associated risk factors such as Type-1 Diabetes or Dyslipidemia
As an adjunct to diet and excercise for treatment of Obese patients.
Adverse Reaction:
Rimonabant treatment showed an excellant tolerance among patients except for some mild gastrointestinal adverse effects at the highest dose administered
Safety data from preliminary results of the RIO- Lipids, RIO -Europe, and RIO-America - trials revealed that Rimonabant is well tolerated aming patients efects
Most frequently reported adverse effects are- Dizziness, Upper respiratory Infections
Diarrhoea was seen most commonly in the RIO- Europe tria ( 2.%, 5.5% and 7.8% for placebo Roimonabant 5mg//day and 20mg /day respy.
Side effects were mild, transient, self-limiting and occured early in the treatment period.
The most important side effects included nausea, dizzines, diarrhoea, vomiting, self reported hypoglycemia, fatigue and anxiety.
Dosages/ Overdosage Etc:
Approvedby US FDA in February 2006
For obese patients BMI 30kg/M2 or overweight patients BMI 27kg/M2
with associated risk factors such as Type-1 Diabetes or Dyslipidemia
As an adjunct to diet and excercise for treatment of Obese patients.
Dosage- 20mg/day
Pharmacology/ Pharmacokinetics:
Chemistry- Rimonabant is a neurokinin - 3 antagonist and selective cannabinoid CBI receptor antagonist currently being reseached and deveoped. The Chemical name- N-piperino5 -(4 chlorophenyl) - 1 -(2,4-dichlorophenyl ) -4 -methyl pyrazole -3 carboxamide Mechanism of Action- Rimonabant is te first in a new class of agents that act by selectively blocking the cannabinoid -1 receptors with resultant central and metabolic peripheral effects, therby decreasing food intake and increases energy expenditure CB1 receptors are present both in the cNS as well as in certain peripheral tissues like adipocytes, gastointestinal tract and liver. Rimonabant is reported to possess a 1000- fold affinity for CB1 receptor than CB2 receptor.
Pharmacokinetics-
Rimonabant has demonstrated a long duration of action ( 8 hours) and good oral bioavailability Rimonabant is able to antagonise the pharmacologic effects induced by cannabinoid receptor agonists. It powerfully reduces food intake and increases energy expenditure It modulates the rewarding properties of food by inhibiting the action of endogenous cannabinoids at specific mesolimbic areas. It alters the variety of signals of peripheral origin ( leptin, ghrelin, and adiponectin) which modulate the neurochemical activation of hypthalamic neurons and the stae of relative balance. Rimonabant also inhibits the enzymes involved in lipogenesis.
Interaction with Food:
It powerfully reduces food intake and increases energy expenditure It modulates the rewarding properties of food by inhibiting the action of endogenous cannabinoids at specific mesolimbic areas.
Pregnancy and lactation:
Reports not available
About Us